While venetoclax and metformin monotherapies did not significantly alter human CD45+ levels in peripheral blood (PB) compared to vehicle-treated controls, the combination therapy significantly reduced leukemia burden in PB, bone marrow, and spleen relative to both vehicle and venetoclax monotherapy groups (Supplementary Fig. 4m–o). This evidence concerns the gene PTPRC and leukemia.